Finding nuance and solutions amongst the clutter
Does a trial readout stand up under the microscope
It's time to look to the future beyond plain vanilla ADCs
10 IO topics to watch out for at ASH23
Spotting the winners and losers in the gastric cancer niche
There's a huge surge in ADCs in the clinic but how many will make an impact?
Challenges and opportunities in the myeloma niche
Part 2 of our WCLC 2023 Previews
How exploratory new biomarkers are paving the way
Progress report on a varied China based CAR-T cell program
Where a forgotten costimulator may hold the key to new developments
From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products
There's much more to think about implications from readouts than the scoreboard
We put 10 clinical trials through their paces to ascertain whether they were hype or not
Tackling intractable cancers with a novel and creative approach to the problem
Continuing our coverage of the annual meeting of ASCO in Chicago I felt compelled to review the actual…
What do three phase 1 and one phase 2 trials tell us about future development?
A look at 4 trials with largely unexpected results
Highlights from Day 1 at ASCO23
How does the NATALEE trial stack up in adjuvant HR+/HER2- breast cancer?
Novel KRAS developments to watch out for
Some ASCO23 abstracts to watch out for and why
Update on Developmental Therapeutics
